HRS 2018: Optimizer Cardiac Contractility Device Helps Subset Of Heart-Failure Patients

The FIX-HF-5C trial, a subgroup study derived from the FIX-HF-5 pivotal trial, shows that the Impulse Dynamics Optimizer cardiac contractility modulation device significantly improved exercise tolerance and quality of life in certain heart-failure patients. Results of the trial were presented at the Heart Rhythm Society conference in Boston. Impulse Dynamics expects to file the final PMA module for US FDA for Optimizer in June.

View of the Boston Harbor in Boston, Massachusetts, USA with its mix of modern and historic architecture in a cross processed image.

More from Clinical Trials

More from R&D